Abamune L is a combination tablet that contains Abacavir (300mg) and Lamivudine (300mg), antiretroviral medications used to treat human immunodeficiency virus (HIV) infection in adults and children.
Composition:
- Abacavir: 300mg
- Lamivudine: 300mg
- Tablet core: lactose monohydrate, magnesium stearate, silicon dioxide
- Film coating: hypromellose, polyethylene glycol, titanium dioxide
Mechanism of Action:
Abamune L works by inhibiting the activity of HIV reverse transcriptase, an enzyme necessary for the virus to replicate. The combination of Abacavir and Lamivudine has a synergistic effect in suppressing HIV replication.
Abacavir:
- Abacavir is a nucleoside reverse transcriptase inhibitor that inhibits the activity of HIV reverse transcriptase.
- It is converted into its active form, abacavir triphosphate, which is incorporated into the viral DNA, terminating the chain and preventing the virus from replicating.
Lamivudine:
- Lamivudine is a nucleoside reverse transcriptase inhibitor that inhibits the activity of HIV reverse transcriptase.
- It is converted into its active form, lamivudine triphosphate, which is incorporated into the viral DNA, terminating the chain and preventing the virus from replicating.
Uses:
Abamune L is used to treat HIV infection in adults and children. It is recommended for patients who have not previously received antiretroviral therapy or who have failed other antiretroviral regimens.
Dosage:
The recommended dosage of Abamune L is one tablet twice daily, taken with food.
Side Effects:
Common side effects of Abamune L include:
- Headache
- Nausea
- Vomiting
- Fatigue
- Dizziness
- Insomnia
- Rash
- Abnormal dreams
- Increased blood lipids
- Neuropathy (nerve damage)
- Lactic acidosis (build-up of lactic acid in the blood)
Recommendation:
Abamune L should be used under the guidance of a healthcare professional. Patients should be monitored regularly for liver function tests, lipid profiles, and glucose levels.
Important Note:
- Abamune L is not recommended for use in patients with severe liver disease (Child-Pugh C).
- Patients with pre-existing kidney disease should be monitored closely for signs of kidney damage or toxicity.
- Patients taking other medications, including antiretroviral agents, may be at risk for interactions with Abamune L.
- The safety and efficacy of Abamune L in pregnant or lactating women have not been established.
- Patients should be counseled on the importance of taking concomitant therapy as prescribed by their healthcare provider.
- Patients should be monitored for neuropsychiatric symptoms, such as depression, anxiety, and sleep disorders.
Reviews
There are no reviews yet.